Tafasitamab + Lenalidomide for Non-Hodgkin's Lymphoma
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are currently receiving or have recently received any investigational study agent, you may not be eligible to participate.
What data supports the effectiveness of the drug combination Tafasitamab and Lenalidomide for treating Non-Hodgkin's Lymphoma?
Research shows that the combination of Tafasitamab and Lenalidomide is effective for patients with relapsed or refractory diffuse large B-cell lymphoma, a type of Non-Hodgkin's Lymphoma. In a study, 57.5% of patients responded to the treatment, with 41.3% achieving complete response, and the treatment was well-tolerated with manageable side effects.12345
Is the combination of Tafasitamab and Lenalidomide safe for treating non-Hodgkin's lymphoma?
How is the drug combination of Tafasitamab and Lenalidomide unique for treating Non-Hodgkin's Lymphoma?
The combination of Tafasitamab and Lenalidomide is unique because it targets CD19 on cancer cells and enhances the immune response, offering a new option for patients with relapsed or refractory diffuse large B-cell lymphoma who cannot undergo stem cell transplants. This combination has shown promising long-term benefits and manageable side effects, making it a novel approach compared to other treatments.12458
What is the purpose of this trial?
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Research Team
Frederick Locke, MD
Principal Investigator
Moffitt Cancer Center
Eligibility Criteria
This trial is for individuals with Large B Cell Lymphoma who have previously undergone axicabtagene ciloleucel treatment. Participants will be involved in the study for approximately 12 months.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Tafasitamab intravenously weekly for the first three 28-day cycles and every 2 weeks starting at Cycle 4. Lenalidomide is taken daily for 21 days out of each 28-day cycle for 6 cycles.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Lenalidomide
- Tafasitamab
Find a Clinic Near You
Who Is Running the Clinical Trial?
H. Lee Moffitt Cancer Center and Research Institute
Lead Sponsor
Incyte Corporation
Industry Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School